| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/10/2010 | US20100143352 Combination therapy for b cell disorders |
| 06/10/2010 | US20100143351 Anti-Angiogenesis Therapy for the Treatment of Breast Cancer |
| 06/10/2010 | US20100143350 Combination of a purine-based cdk inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders |
| 06/10/2010 | US20100143349 Humanized anti-rage antibody |
| 06/10/2010 | US20100143348 OVR115 Antibody Compositions and Methods of Use |
| 06/10/2010 | US20100143345 Epha2 agonistic monoclonal antibodies and methods of use thereof |
| 06/10/2010 | US20100143324 Method for treatment of cancers or inflammatory diseases |
| 06/10/2010 | US20100143315 Method for Improving the Specific Effector Function of Single-Chain Antigen-Recognizing Genetic Constructs (SCARC) Through Murinization Thereof |
| 06/10/2010 | US20100143312 Treatment of diseases, disorders or conditions of the lung using placental cells |
| 06/10/2010 | US20100143311 Anticancer therapy by transplanting vascular endothelial progenitor cells |
| 06/10/2010 | US20100143309 Viral vectors |
| 06/10/2010 | US20100143298 Colloidal metal compositions and methods |
| 06/10/2010 | US20100143296 Podophyllotoxin inhibitors of topoisomerase ii |
| 06/10/2010 | US20100143295 Quinazoline inhibitors of egfr tyrosine kinase |
| 06/10/2010 | US20100143294 Antagonists of il-6 to prevent or treat thrombosis |
| 06/10/2010 | US20100143291 Inactivated pepsin fragments for modulating immune system activity against human malignant tumor cells |
| 06/10/2010 | US20100143275 Canola Extracts Containing High Levels of Phenolic Acids |
| 06/10/2010 | US20100143270 Therapeutic cotinine compositions |
| 06/10/2010 | US20100143257 Prevention of Cancers by Immunization |
| 06/10/2010 | US20100143246 Interleukin 17 Receptor-Like Protein |
| 06/10/2010 | US20100143245 Uses of monoclonal antibody 8h9 |
| 06/10/2010 | US20100140131 Production of an Oxaliplatin Mixture and a Container and a Container Set for Said Mixture |
| 06/10/2010 | DE102008061214A1 Chinazolinamidderivate Chinazolinamidderivate |
| 06/10/2010 | CA2745919A1 Compositions and methods relating to mir-31 |
| 06/10/2010 | CA2745832A1 Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms |
| 06/10/2010 | CA2745811A1 Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
| 06/10/2010 | CA2745746A1 Microrna-based methods and compositions for the diagnosis and treatment of ovarian cancer |
| 06/10/2010 | CA2745499A1 Peptide therapeutic conjugates and uses thereof |
| 06/10/2010 | CA2745495A1 Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals |
| 06/10/2010 | CA2745415A1 Methods for preventing or reducing carcinogenesis or oxidative stress |
| 06/10/2010 | CA2745408A1 Wdrpuh epitope peptides and vaccines containing the same |
| 06/10/2010 | CA2745356A1 2h-chromene compound and derivative thereof |
| 06/10/2010 | CA2745224A1 Methods for preventing or reducing colon carcinogenesis |
| 06/10/2010 | CA2745144A1 Benzothiazole derivatives as anticancer agents |
| 06/10/2010 | CA2745065A1 Compounds for treating proliferative disorders |
| 06/10/2010 | CA2744713A1 Raf inhibitors and their uses |
| 06/10/2010 | CA2744711A1 Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| 06/10/2010 | CA2744708A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| 06/10/2010 | CA2744065A1 Process for the modulation of the antagonistic activity of a monoclonal antibody |
| 06/10/2010 | CA2743785A1 Bis[o-(14-benzoylaconine-8-yl)] esters |
| 06/10/2010 | CA2743592A1 Kinase inhibitors with improved cyp safety profile |
| 06/10/2010 | CA2740347A1 Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms |
| 06/09/2010 | EP2194144A1 Roles for dual Endothelin-1/Angiotensin II receptor (DEAR) in hypertension and angiogenesis |
| 06/09/2010 | EP2194130A1 Cytokine ZCYTO18 |
| 06/09/2010 | EP2194067A2 Antibodies to insulin-like growth factor I receptor (IGF-IR) |
| 06/09/2010 | EP2194061A1 HC-Toxin as means for treating advanced stage neuroblastoma |
| 06/09/2010 | EP2194057A1 Stable crystalline salts of 5-methyltetrahydrofolic acid |
| 06/09/2010 | EP2194049A1 N-oxides of N-phenyl-2-pyrimidine-amine derivatives |
| 06/09/2010 | EP2194045A1 Substituted pyrazole derivative |
| 06/09/2010 | EP2194044A1 Quinolone derivative |
| 06/09/2010 | EP2193805A1 Immunosuppression weaning agent comprising tumor cell and antitumor agent using the same |
| 06/09/2010 | EP2193804A2 Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens |
| 06/09/2010 | EP2193791A1 The treatment of respiratory diseases |
| 06/09/2010 | EP2193788A1 Pharmaceutical compositions comprising colloidal silicon dioxide |
| 06/09/2010 | EP2193147A1 Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and use thereof |
| 06/09/2010 | EP2193130A1 Pyrazolo-pyridines as tyrosine kinase inhibitors |
| 06/09/2010 | EP2193127A1 Benzothiazole compounds |
| 06/09/2010 | EP2193119A1 4-(4-pyridinyl)-benzamides and their use as rock activity modulators |
| 06/09/2010 | EP2193118A2 Piperidine and piperazine derivatives for treating tumours |
| 06/09/2010 | EP2192921A1 Intraoperative trifunctional antibody administration for prophylaxis of intraperitoneal tumor cell dissemination |
| 06/09/2010 | EP2192919A1 Methods of inhibiting tumor growth using beta 5 integrin antagonists |
| 06/09/2010 | EP2192915A1 Therapeutic uses of peptides ysaypdsvpmms and wmnstgftkvcgappc |
| 06/09/2010 | EP2192912A1 Essential oil of kunzea ambigua and methods of use |
| 06/09/2010 | EP2192835A1 Treatment of lung cancer |
| 06/09/2010 | EP2049508B1 N-hydroxy-3-(4-{3-phenyl-3-oxo-propenyl}-phenyl)-acrylamide derivatives and related compounds as histone deacetylase inhibitors for the treatment of cancer |
| 06/09/2010 | EP1999126B1 Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53 |
| 06/09/2010 | EP1934224B1 Pyrazolopyrimidines as cyclin dependent kinase inhibitors for the treatment of cancer |
| 06/09/2010 | EP1919463B1 Use of hif 1alfa modulators for treatment of cancer |
| 06/09/2010 | EP1653990B1 Use of polypeptides of the cupredoxin family in cancer therapy |
| 06/09/2010 | EP1497273B1 Hydroxamic acid derivatives |
| 06/09/2010 | EP1385864B1 Anti-VEGF-2 antibodies |
| 06/09/2010 | EP1292308B1 Alpha,beta-unsaturated sulfones for treating proliferative disorders |
| 06/09/2010 | EP1228087B1 Antibody catalysis of enantio- and diastereo-selective aldol reactions |
| 06/09/2010 | EP0951295B1 Compositions for use in inhibiting of alpha-v-beta3 mediated angiogenesis |
| 06/09/2010 | CN1994289B Application of dibenzocyclootadiene lignans in preparation of tyrosine-inhibiting medicine |
| 06/09/2010 | CN1982324B Oncogene, recombinant protein derived therefrom, and uses thereof |
| 06/09/2010 | CN1974759B Attenuated salmonella transporting recombinant plasmid and its application in treating tumor |
| 06/09/2010 | CN1902159B Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents |
| 06/09/2010 | CN1882589B Novel heterocyclic compounds as HSP90-inhibitors |
| 06/09/2010 | CN1868485B Medicine composition and its application |
| 06/09/2010 | CN1834108B Acanthopanax giraldii Harms compound polysaccharide, preparation technique, uses and its compound polysaccharide composition |
| 06/09/2010 | CN1796382B A category of compound of new macrolide, preparation method and application |
| 06/09/2010 | CN1780835B Novel fused heterocycles and uses thereof |
| 06/09/2010 | CN1735607B 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer |
| 06/09/2010 | CN1679957B A pharmaceutical composition containing liposomes for treating a cancer |
| 06/09/2010 | CN1646115B Use of SARMS in preparing medicine for treating benign prostate hyperplasia |
| 06/09/2010 | CN1628828B Chinese medicine for preventing and resisting cancer |
| 06/09/2010 | CN1517437B Vaccine for specificity treating tumour or endocellular infection and application |
| 06/09/2010 | CN101730701A Hydrated crystalline esters of camptothecin for the treatment of cancer |
| 06/09/2010 | CN101730700A Condensed heterocyclic compounds as inhibitors of protein kinases |
| 06/09/2010 | CN101730699A Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
| 06/09/2010 | CN101730697A Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
| 06/09/2010 | CN101730549A polymers conjugated with platinum drugs |
| 06/09/2010 | CN101730547A Drug combination and its use in the treatment of muscle loss |
| 06/09/2010 | CN101730533A Stable pharmaceutical composition comprising a hydrosoluble vinflunine salt |
| 06/09/2010 | CN101730526A Nanoparticle comprising rapamycin and albumin as anticancer agent |
| 06/09/2010 | CN101724667A Technology for extracting dendrobium polysaccharide by applying biology engineering enzyme technology and product thereof and application |
| 06/09/2010 | CN101724631A Preparation of functional area of sea purse blood vessel growth inhibition factor 1 and use of the functional area of sea purse blood vessel growth inhibition factor 1 in medicaments for preventing and curing tumors |
| 06/09/2010 | CN101724599A Use of dendrimers to stimulate cell growth |
| 06/09/2010 | CN101724091A Active carboxymethylpachymaran, production process and application thereof |